Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability
Autor: | Linda Williams, M. McHugh, Oliver M. Dixon, J. Murray, Lorna Renshaw, Lesley Fallowfield, FM McCaig, E. Jane Macaskill, O. Young, C. Langridge, J Michael Dixon |
---|---|
Přispěvatelé: | Edinburgh Breast Unit, Western General Hospital, CRUK Sussex Psychosocial Oncology Group, Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Public Health Sciences, University of Edinburgh |
Jazyk: | angličtina |
Rok vydání: | 2010 |
Předmět: |
Adult
Oncology Quality of life Cancer Research medicine.medical_specialty Antineoplastic Agents Hormonal medicine.drug_class Anastrozole Antineoplastic Agents Breast Neoplasms Endocrine System 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Nitriles medicine Adjuvant therapy Humans Aged 030304 developmental biology Aged 80 and over Gynecology 0303 health sciences Cross-Over Studies Aromatase inhibitor business.industry Letrozole Middle Aged Triazoles medicine.disease 3. Good health Tamoxifen Treatment Outcome Tolerability 030220 oncology & carcinogenesis business medicine.drug |
Zdroj: | Breast Cancer Research and Treatment Breast Cancer Research and Treatment, Springer Verlag, 2010, 125 (3), pp.741-749. ⟨10.1007/s10549-010-1091-9⟩ |
ISSN: | 0167-6806 1573-7217 |
Popis: | International audience; Previous studies have demonstrated that both anastrozole and letrozole are well tolerated. Letrozole suppresses estrogen to a greater degree than anastrozole in the serum and breast tumor. Concerns have been raised that greater potency may adversely affect patients' quality of life (QOL). One hundred eighty-one postmenopausal women with invasive estrogen receptor-positive breast cancers were randomized to receive either 12 weeks of letrozole followed by 12 weeks of anastrozole or the reverse sequence. One hundred and six received immediate adjuvant aromatase inhibitors (AIs) following surgery, and 75 received extended adjuvant therapy. The Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-B-ES) QOL questionnaires were completed to assess QOL on each drug. Additional side-effect profiles were collected. Each patient completed a patient preference form. Twenty-one patients withdrew before study end, 10/179 (5.6%) while taking letrozole and 4/173 (2.3%) while taking anastrozole ( = 0.12). Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; = 0.001). There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs. Nearly 80% of patients reported one or more side effects with either agent. No differences in frequency, grade, or range of side effects were seen between drugs. Of 160 patients, 49 (30.6%) preferred letrozole, 57 (35.6%) preferred anastrozole, and 54 (33.8%) had no preference ( = 0.26, Pearson's Chi-squared test). In conclusion, both AIs are equally well tolerated. There were no significant differences in QOL scores between the two drugs. |
Databáze: | OpenAIRE |
Externí odkaz: |